Ozempic’s Expanded Approval Propels Novo Nordisk to the Top of GLP-1 Market | #chronic Kidney Disease # chronic kidney disease market # GLP-1 receptor # GLP-1R/GIPR agonist
Like
Comment
Ozempic’s Expanded Approval Propels Novo Nordisk to the Top of GLP-1 Market | #chronic Kidney Disease # chronic kidney disease market # GLP-1 receptor # GLP-1R/GIPR agonist